Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.62 |
| ▸ | PIK3CD | O00329 | 10/20 | 0.62 |
| ▸ | PIK3CB | P42338 | 9/20 | 0.62 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.62 |
| ▸ | ABL1 | P00519 | 1/20 | 0.55 |
| ▸ | KIT | P10721 | 1/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.55 |
| ▸ | PI4KA | P42356 | 11/20 | 0.53 |
| ▸ | PI4KB | Q9UBF8 | 11/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | PIP5K1C | O60331 | 4/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.48 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20855252 | 0.82 | ABL1 (0.58) | HTTGAAL3MBTL1PIK3CAPIK3CD | |
| SCHEMBL3306309 | 0.81 | PIK3CA (0.74) | HTTGAAL3MBTL1PIK3CAPIK3CD | |
| SCHEMBL31298 | 0.80 | HTT (1.00) | HTTGAAL3MBTL1PIK3CAPIK3CD | |
| Hydrochloric Acid SCHEMBL11729261 | 0.78 | HTT (0.96) | HTTGAAL3MBTL1PIK3CAPIK3CD | |
| SCHEMBL20865379 | 0.78 | PIK3CD (0.62) | PIK3CAPIK3CDPIK3CBPIK3CGABL1 | |
| SCHEMBL20887499 | 0.77 | DYRK1A (0.72) | PIK3CAPIK3CGABL1KITPDGFRA | |
| SCHEMBL29646253 | 0.77 | PIK3CA (0.82) | HTTGAAL3MBTL1PIK3CAPIK3CD | |
| SCHEMBL5532470 | 0.77 | PIK3CA (0.82) | HTTGAAL3MBTL1PIK3CAPIK3CD | |
| SCHEMBL20855175 | 0.75 | CYP3A4 (0.47) | HTTGAAPIK3CAPIK3CDPIK3CB | |
| SCHEMBL20855178 | 0.75 | PIK3CA (0.64) | HTTGAAPIK3CAPIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111315727-B | Benzothiazole compounds and methods of treating neurodegenerative diseases using the same | 第一生物治疗股份有限公司 | 2023-09-29 | — | — | CN | disclosed |
| EP-3692023-B1 | BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS | 1ST BIOTHERAPEUTICS INC (KR) | 2023-05-17 | — | — | EP | disclosed |
| EP-3692023-B1 | BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS | 1ST BIOTHERAPEUTICS INC (KR) | 2023-05-17 | — | — | EP | disclosed |
| US-10968188-B2 | Benzothiazol compounds and methods using the same for treating neurodegenerative disorders | 1ST Biotherapeutics, Inc. (KR) | 2021-04-06 | — | — | US | disclosed |
| US-10968188-B2 | Benzothiazol compounds and methods using the same for treating neurodegenerative disorders | 1ST Biotherapeutics, Inc. (KR) | 2021-04-06 | — | — | US | disclosed |
| US-20200270222-A1 | BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. | 2020-08-27 | — | — | US | disclosed |
| US-20200270222-A1 | BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. | 2020-08-27 | — | — | US | disclosed |
| EP-3692023-A1 | BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS | 1st Biotherapeutics, Inc. (KR) | 2020-08-12 | — | — | EP | disclosed |
| US-10669246-B2 | Benzothiazol compounds and methods using the same for treating neurodegenerative disorders | 1ST Biotherapeutics, Inc. (KR) | 2020-06-02 | — | — | US | disclosed |
| US-10669246-B2 | Benzothiazol compounds and methods using the same for treating neurodegenerative disorders | 1ST Biotherapeutics, Inc. (KR) | 2020-06-02 | — | — | US | disclosed |
| WO-2019070093-A1 | BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. (KR) | 2019-04-11 | — | — | WO | disclosed |
| WO-2019070093-A1 | BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. (KR) | 2019-04-11 | — | — | WO | disclosed |
| US-20190100500-A1 | BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. | 2019-04-04 | — | — | US | disclosed |
| US-20190100500-A1 | BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. | 2019-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190100500-A1 | BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS | ABL2, ABL1, MAPT | HTT 20/4885GAA 254/4885L3MBTL1 1651/4885 |
| US-10669246-B2 | Benzothiazol compounds and methods using the same for treating neurodegenerative disorders | ABL2, ABL1, MAPT | HTT 20/4885GAA 254/4885L3MBTL1 1651/4885 |
| US-10968188-B2 | Benzothiazol compounds and methods using the same for treating neurodegenerative disorders | ABL2, ABL1, MAPT | HTT 20/4885GAA 254/4885L3MBTL1 1651/4885 |
| US-20200270222-A1 | BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS | ABL2, ABL1, MAPT | HTT 20/4885GAA 254/4885L3MBTL1 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.